Increased Cross-presentation by Dendritic Cells and Enhanced Anti-tumour Therapy Using the Arp2/3 Inhibitor CK666

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Jan 11

PMID 36631633

Authors

Mariana M S Oliveira

Roberta DAulerio

Tracer Yong

Minghui He

Marisa A P Baptista

Susanne Nylen

Lisa S Westerberg

Affiliations

Soon will be listed here.

Abstract

Background: Dendritic cell (DC) vaccines for cancer therapy offer the possibility to let the patient's own immune system kill cancer cells. However, DC vaccines have shown less efficacy than expected due to failure to induce cancer cell killing and by activating T regulatory cells.

Methods: We tested if inhibition of signalling via WASp and Arp2/3 using the small molecule CK666 would enhance DC-mediated killing of tumour cells in vitro and in vivo.

Results: Using CK666 during the ex vivo phase of antigen processing of ovalbumin (OVA), murine and human DCs showed decreased phagosomal acidification, indicating activation of the cross-presentation pathway. When compared to untreated DCs, DCs treated with CK666 during uptake and processing of OVA-induced increased proliferation of OVA-specific CD8 OT-I T cells in vitro and in vivo. Using the aggressive B16-mOVA melanoma tumour model, we show that mice injected with CK666-treated DCs and OVA-specific CD8 OT-I T cells showed higher rejection of B16 melanoma cells when compared to mice receiving non-treated DCs. This resulted in the prolonged survival of tumour-bearing mice receiving CK666-treated DCs. Moreover, combining CK666-treated DCs with the checkpoint inhibitor anti-PD1 further prolonged survival.

Conclusion: Our data suggest that the small molecule inhibitor CK666 is a good candidate to enhance DC cross-presentation for cancer therapy.

Citing Articles

ELK3-CYFIP2 axis-mediated actin remodeling modulates metastasis and natural killer cell responses in triple-negative breast cancer.

Choi S, Jang H, Park J, Ryu K, Maeng E, Cho S J Exp Clin Cancer Res. 2025; 44(1):48.

PMID: 39930469 PMC: 11808954. DOI: 10.1186/s13046-025-03309-7.

Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.

Sheikhlary S, Lopez D, Moghimi S, Sun B Biomolecules. 2024; 14(4).

PMID: 38672519 PMC: 11048403. DOI: 10.3390/biom14040503.

Unraveling the Multifaceted Roles of Extracellular Vesicles: Insights into Biology, Pharmacology, and Pharmaceutical Applications for Drug Delivery.

Al-Jipouri A, Eritja A, Bozic M Int J Mol Sci. 2024; 25(1).

PMID: 38203656 PMC: 10779093. DOI: 10.3390/ijms25010485.

The Potential of Dendritic Cell Subsets in the Development of Personalized Immunotherapy for Cancer Treatment.

Gorodilova A, Kitaeva K, Filin I, Mayasin Y, Kharisova C, Issa S Curr Issues Mol Biol. 2023; 45(10):8053-8070.

PMID: 37886952 PMC: 10605421. DOI: 10.3390/cimb45100509.

Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations.

Lee K, Yam J, Mao X Cells. 2023; 12(17).

PMID: 37681880 PMC: 10486560. DOI: 10.3390/cells12172147.

References

Bevan M . Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976; 143(5):1283-8. PMC: 2190184. DOI: 10.1084/jem.143.5.1283. View

Jung S, Unutmaz D, Wong P, Sano G, de Los Santos K, Sparwasser T . In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity. 2002; 17(2):211-20. PMC: 3689299. DOI: 10.1016/s1074-7613(02)00365-5. View

Steinman R . The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991; 9:271-96. DOI: 10.1146/annurev.iy.09.040191.001415. View

Kovacsovics-Bankowski M, Rock K . A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 1995; 267(5195):243-6. DOI: 10.1126/science.7809629. View

Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S . Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol. 1999; 1(6):362-8. DOI: 10.1038/14058. View

Colbert J, Cruz F, Rock K . Cross-presentation of exogenous antigens on MHC I molecules. Curr Opin Immunol. 2020; 64:1-8. PMC: 7343603. DOI: 10.1016/j.coi.2019.12.005. View

Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A . Phagosomes are competent organelles for antigen cross-presentation. Nature. 2003; 425(6956):402-6. DOI: 10.1038/nature01912. View

Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, van Endert P, Amigorena S . ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature. 2003; 425(6956):397-402. DOI: 10.1038/nature01911. View

Shen L, Sigal L, Boes M, Rock K . Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation in vivo. Immunity. 2004; 21(2):155-65. DOI: 10.1016/j.immuni.2004.07.004. View

10.

Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C . Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol. 2006; 177(6):3525-33. DOI: 10.4049/jimmunol.177.6.3525. View

11.

Li B, Hu L . Cross-presentation of Exogenous Antigens. Transfus Clin Biol. 2019; 26(4):346-351. DOI: 10.1016/j.tracli.2019.01.006. View

12.

Merzougui N, Kratzer R, Saveanu L, van Endert P . A proteasome-dependent, TAP-independent pathway for cross-presentation of phagocytosed antigen. EMBO Rep. 2011; 12(12):1257-64. PMC: 3245693. DOI: 10.1038/embor.2011.203. View

13.

Joffre O, Segura E, Savina A, Amigorena S . Cross-presentation by dendritic cells. Nat Rev Immunol. 2012; 12(8):557-69. DOI: 10.1038/nri3254. View

14.

Fu C, Zhou L, Mi Q, Jiang A . DC-Based Vaccines for Cancer Immunotherapy. Vaccines (Basel). 2020; 8(4). PMC: 7712957. DOI: 10.3390/vaccines8040706. View

15.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

16.

Baptista M, Keszei M, Oliveira M, Sunahara K, Andersson J, Dahlberg C . Deletion of Wiskott-Aldrich syndrome protein triggers Rac2 activity and increased cross-presentation by dendritic cells. Nat Commun. 2016; 7:12175. PMC: 4960314. DOI: 10.1038/ncomms12175. View

17.

Binks M, Jones G, Brickell P, Kinnon C, Katz D, Thrasher A . Intrinsic dendritic cell abnormalities in Wiskott-Aldrich syndrome. Eur J Immunol. 1998; 28(10):3259-67. DOI: 10.1002/(SICI)1521-4141(199810)28:10<3259::AID-IMMU3259>3.0.CO;2-B. View

18.

De Noronha S, Hardy S, Sinclair J, Blundell M, Strid J, Schulz O . Impaired dendritic-cell homing in vivo in the absence of Wiskott-Aldrich syndrome protein. Blood. 2004; 105(4):1590-7. DOI: 10.1182/blood-2004-06-2332. View

19.

Machesky L, Mullins R, Higgs H, Kaiser D, Blanchoin L, MAY R . Scar, a WASp-related protein, activates nucleation of actin filaments by the Arp2/3 complex. Proc Natl Acad Sci U S A. 1999; 96(7):3739-44. PMC: 22364. DOI: 10.1073/pnas.96.7.3739. View

20.

Thrasher A, Burns S . WASP: a key immunological multitasker. Nat Rev Immunol. 2010; 10(3):182-92. DOI: 10.1038/nri2724. View